You are here:
Direct Healthcare Professional Communication (DHPC) on Miltefosin (Impavido® 10 mg/50 mg Capsules): new warning about ocular changes, including keratitis
2021.02.05
Active substance: miltefosine
The company Paesel und Lorei GmbH & Co. KG informs in coordination with the Federal Institute for Drugs and Medical Devices (BfArM) that in a few case reports complications of the eye (including keratitis) occurred under treatment with miltefosine, in most cases with a treatment duration of more than 28 days. Patients should be advised to contact the prescribing physician immediately in case of eye complaints.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN